StemBioSys develops HPMETM, a proprietary advanced stem cell culture system that replicates the 3D microenvironment in which stem cells naturally reside. The technology enables isolation and growth of stem cells from adipose, bone marrow and umbilical cord blood/tissue, supporting faster replication and better preservation of stem cell phenotype versus traditional tissue culture plastic. The company closed an $8M Series A to fund a GMP manufacturing facility and market preparations for a targeted mid‑2015 research-product launch. StemBioSys is pursuing therapeutic applications through more than 14 strategic partner collaborations and multiple sponsored research agreements, including with UT Health Science Center at San Antonio, UTSA, and Langer/Anderson Laboratories at MIT. Founded in 2010 and based in San Antonio, the privately held company plans a Series B in late 2015/early 2016 to complete commercial launch and continue exploring therapeutic uses. Proceeds from the Series A will be used primarily to build GMP manufacturing capacity and support commercialization activities. StemBioSys develops and manufactures stem cell technologies focused on regenerative medicine. The company highlights its patented XC-marrow ECM™, an extracellular matrix laid down by human bone marrow mesenchymal stem cells that creates a 3D microenvironment to preserve stem cell phenotypes. The XC-marrow ECM™ enables faster replication and better preservation of “stemness” compared with traditional tissue culture plastic and lets SBS grow stem cells from adipose tissue, bone marrow and umbilical cord blood. StemBioSys positions the product for research, pharmaceutical and novel clinical uses and frames the XC-marrow ECM™ as the centerpiece of its expansion. Financially, a regulatory filing shows the company has landed $2,377,802 and is seeking an additional $5,622,198. The company is in a quiet period of funding that Chairman Dr. Steve Davis said should end Aug. 5; officers named in the article include Dr. Steve Davis, Dr. Xiao-Dong Chen, Edward “Sy” Griffey and CEO Peter Savas.

Total raised

$10M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2015